EP
ADAP

Eversept Partners’s Adaptimmune Therapeutics ADAP Stock Holding History

Eversept Partners’s Portfolio ADAP Stock Details ADAP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-237,086
Closed -$488K – 78
2022
Q1 		$488K Sell
237,086
-111,630
-32% -$301K 0.04% 76
2021
Q4 		$1.31M Sell
348,716
-96,171
-22% -$438K 0.08% 85
2021
Q3 		$2.3M Buy
+444,887
New +$2M 0.16% 72

Other funds holding ADAP

MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
ECM
Endurant Capital Management San Mateo, California $17.4M AUM 7.38% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Eversept Partners's ADAP Position: Q2 2022 in Review

Eversept Partners sold out of Adaptimmune Therapeutics (ADAP) in Q2 2022, closing a stake of 237,086 shares — an estimated $488K sold.

Eversept Partners first reported a position in ADAP in Q3 2021 and held it in 3 quarters. The position peaked at $2.3M in Q3 2021. 77 funds tracked by Wall St. Rank hold ADAP as of Q2 2022.

  • Eversept Partners reported no remaining Adaptimmune Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Eversept Partners sold 237,086 Adaptimmune Therapeutics shares in Q2 2022, an estimated $488K.
  • Eversept Partners first reported a position in Adaptimmune Therapeutics in Q3 2021 and held it in 3 quarters.
  • Eversept Partners's Adaptimmune Therapeutics position peaked at $2.3M in Q3 2021.
  • 77 funds tracked by Wall St. Rank held Adaptimmune Therapeutics as of Q2 2022.

Based on Eversept Partners's 13F filing for Q2 2022, filed 15 Aug 2022.